COMPANY:

PreludeDx

P=NA | N=NA | "Prelude Corporation...announced results of a cutting-edge study in Clinical Breast Cancer....The study evaluated HER2-positive patients treated with breast conserving surgery (BCS) plus radiation therapy (RT) to determine if the DCISionRT test could identify those patients with elevated residual risk remaining after treatment. The study showed that patients with the DCISionRT Residual Risk subtype had significantly higher in-breast recurrence (IBR) rates compared to those without the Residual Risk subtype (16.2% vs 1.6%, p=.01)....DCISionRT successfully identified two distinct groups of HER2(3+) DCIS patients treated with breast-conserving surgery (BCS) plus radiation therapy (RT) that could not be identified using traditional clinicopathologic factors."

"Prelude Corporation...and Cancer Help Desk, have partnered to provide expert nurse navigation services for women diagnosed with ductal carcinoma in situ (DCIS) breast cancer. This alliance allows for direct engagement between newly diagnosed DCIS patients seeking assistance with clinical options and healthcare professionals trained in breast cancer patient navigation....This novel collaboration within the diagnostic laboratory testing space demonstrates a shared commitment to empowering patients with tools needed to inform their treatment decision-making and planning processes."

"Prelude Corporation...announced an important advancement in the field of breast cancer care with the publication of the PREDICT study in the Annals of Surgical Oncology (ASO)....Significant impact on treatment decisions: DCISionRT test results led to a change in pre-test to post-test RT recommendations for 38% of women, highlighting its clinical utility in optimizing treatment plans based on individual patient risk profiles. Net reduction in RT recommendations: Overall, the test contributed to a 20% net reduction in the number of women recommended for RT, potentially sparing many from unnecessary treatment and associated side effects."

"Prelude Corporation...announced that it will share data demonstrating the power of its DCISionRT test to better predict radiation therapy (RT) benefit in comparison to clinicopathologic risk factors for women with ductal carcinoma in situ (DCIS) at The American Society of Clinical Oncology (ASCO), to be held on May 31 – June 4, 2024 at the McCormick Place in Chicago....Of particular importance, the DCISionRT biosignature identified a low-risk group of patients with no significant benefit from ET or RT after breast-conserving surgery."

"Prelude Corporation (PreludeDx™)...presented data on the use of DCISionRT® to identify a subset of patients with high-risk clinicopathology who had a low 10-year risk of in-breast recurrence (IBR) and no significant benefit from radiation therapy (RT). In contrast, patients who had both high risk DCISionRT and high-risk clinicopathology had high 10-year IBR rates and significant RT benefit. The data was presented at the 25th American Society of Breast Surgeons (ASBrS) Annual Meeting, held on April 10 – 14, 2024 at the Orlando World Center Marriott."

"Prelude Corporation...announced that data will be highlighted in a Quickshot Scientific Session and poster presentation at the 25th American Society of Breast Surgeons (ASBrS) Annual Meeting, to be held on April 10 - 14, 2024 at the Orlando World Center Marriott."

"Prelude Corporation (PreludeDx™)...has unveiled data from an analysis of over 700 early-stage invasive breast cancer patients for AidaBreast™ - a novel biosignature that predicts 10-year recurrence rate and radiation therapy (RT) benefit - at the 41st Annual Miami Breast Cancer Conference (MBCC)."

"Prelude Corporation...today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast Cancer Conference (MBCC), held on March 7 – 10, 2024 at the Fontainebleau, Miami Beach, FL....'We are excited to share data regarding our novel biosignature for invasive Stage I, II breast cancer test for radiation therapy, as well as clinical utility data on our DCISionRT test for DCIS at the prestigious MBCC conference.'"

P=NA | N= 483 | "Prelude Corporation...announced it will present data demonstrating the decision impact on physician recommendations for radiation therapy (RT) in ductal carcinoma in situ (DCIS) patients in Australia. The data will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), held on December 5 - 9, 2023 at the Henry B. Gonzalez Convention Center, San Antonio, Texas. The poster...demonstrates that the use of DCISionRT resulted in significant changes in recommendations to add or omit RT compared to clinicopathologic factors (CP) alone. Specifically, in the interim analysis of 483-patients treated with breast conserving surgery in Australia, the use of the test resulted in a 41% change in RT recommendations and a 9% change in hormone therapy (HT) recommendations."

P=NA | N=NA | "Prelude Corporation...announced it will be presenting data on a novel biosignature that predicts radiation therapy (RT) benefit in invasive (Stage I, II) breast cancer patients. The data will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), held on December 5 - 9, 2023 at the Henry B. Gonzalez Convention Center, San Antonio, Texas....While RT following breast conserving surgery was associated with a reduction for recurrence rates (HR=0.3, 95%CI [0.1, 0.5], p<0.001) in the overall patient population, in multivariable analysis, the biosignature was predictive for RT benefit adjusted for clinicopathologic factors, where patients identified as 'Residual-Risk' by the biosignature had a higher ipsilateral breast recurrence rate after RT compared to other risk groups with a positive interaction with RT (HR=3.7 95%CI [1.6,8.7], p=.0026)."

"Prelude Corporation...today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS), held on December 5 - 9, 2023 at the Henry B. Gonzalez Convention Center, San Antonio, Texas....'We are pleased to present additional data on the development of our invasive Stage 1/2 breast cancer test for radiation therapy, as well as expanded international data from our PREDICT Australia study at the prestigious SABCS.'"

P=NA| N=926 | "Prelude Corporation...announced study results of 926 women demonstrating that DCISionRT^®, the 7-gene biosignature for patients with ductal carcinoma in situ (DCIS), reclassified Clinical Pathologic (CP) Low-Risk patients defined by RTOG-9804 and MSKCC-like DCIS models as DCISionRT High-Risk....The oral presentation...demonstrated that patients reclassified into the DCISionRT Low-Risk group had a 10-yr IBR risk of 5.6% after breast conserving surgery (BCS) and no significant RT benefit (0.8% absolute RT benefit, p-0.70), demonstrating a 99% negative predictive value (NPV) for RT benefit. Conversely, the study also demonstrated patients reclassified into the DCISionRT High-Risk groups had higher IBR rates without RT (20% and 12%) and significant absolute IBR rate reductions (13% and 8%) from RT."